Summary: A new study reveals that certain genetic factors may protect against ALS, enabling partial or full recovery. Researchers found that a specific genetic variation reduces a protein blocking the IGF-1 pathway, which is crucial for motor neuron protection. This discovery provides a potential new approach for ALS treatment. The findings highlight the importance of further studying the IGF-1 pathway in ALS therapy.
Key Facts:
- Certain genetic factors may allow partial or full recovery from ALS.
- A specific SNP reduces a protein that blocks the protective IGF-1 pathway.
- The study suggests a new approach to targeting the IGF-1 pathway for ALS treatment.
Source: Duke University
Though exceedingly rare, some people diagnosed with amyotrophic lateral sclerosis (ALS) partially or fully recover from the lethal neurodegenerative disease.
A better understanding of this baffling phenomenon, reported in medical literature for at least 60 years, could point to potential new treatment approaches. To that end, researchers at Duke Health and St. Jude’s Research Hospital launched a study of ALS recovery patients and found certain genetic factors that appear to protect against the disease’s typical assault on motor neurons.
The findings appear in the journal Neurology, the medical journal of the American Academy of Neurology.
“With other neurological diseases, there are now effective treatments,” said Richard Bedlack, M.D., Ph.D., the Stewart, Hughes, and Wendt Professor in the Department of Neurology at Duke University School of Medicine.
“But we still don’t have great options for these patients, and we desperately need to find things. This work provides a starting point to explore how biological reversals of ALS occur and how we might be able to harness that effect therapeutically.”
Bedlack and colleagues – including co-lead author Jesse Crayle, M.D., who is now at Washington University in St. Louis – conducted a genome-wide association study of 22 participants who had been diagnosed with ALS and recovered, comparing them to similar patients whose ALS progressed. Researchers at St. Jude Children’s Research Hospital led the genetic analysis.
“Our whole genome sequencing pipeline leveraged a multiomics strategy to combine newly available gene expression and epigenetic data, and maximized not just this unique dataset but the CReATe and TargetALS patient databases,” explained co-lead author Evadnie Rampersaud, Ph.D., St. Jude Children’s Research Hospital Center for Applied Bioinformatics. She stated that the finding was made possible because the patient samples were characterized so well.
The team identified a common genetic variation called a single nucleotide polymorphism (SNP). The SNP reduces levels of a protein that blocks the IGF-1 signaling pathway, and study participants with this one-letter change in their DNA were 12 times more likely to have experienced a recovery than those without it.
IGF-1 is a growth factor that has long been a target of interest in ALS research because of its role in protecting the motor neurons. ALS patients with fast progression of disease have lower levels of IGF-1 protein, but clinical trials aimed at raising their IGF-1 levels have had disappointing results.
The current finding provides a potential new approach to targeting IGF-1.
“This suggests that the IGF-1 pathway should be further studied as a potential target for future ALS treatments,” Crayle said.
“While it may not be effective to simply give people IGF-1, our study indicates we might have a way to go about it differently by reducing the levels of this inhibiting protein. It is also possible that the prior studies with IGF-1 were just not adequately dosed or need to be dosed in a different way.”
Bedlack said the research team is now exploring whether there is a correlation between the blocking protein and disease progression in a much larger number of patients. Results of that analysis will inform whether a clinical trial targeting this protein could be launched.
In addition to Bedlack and Crayle, study authors include Jason Myers, Joanne Wuu, J. Paul Taylor, Gang Wu and Michael Benatar.
Funding: The study received funding support from the Duke ALS Patient Gift Fund, ALSAC – the fundraising and awareness organization of St. Jude Children’s Research Hospital; the ALS Association (grants 17-LGCA-331 and 16-TACL-242); the CReATe Consortium (U54NS092091), which is part of the NIH Rare Diseases Clinical Research Network (RDCRN; and the National Cancer Institute (P30 CA021765).
About this ALS and genetics research news
Author: Sarah Avery
Source: Duke University
Contact: Sarah Avery – Duke University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype” by Richard Bedlack et al. Neurology
Abstract
Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype
Background and Objectives
The term “ALS Reversal” describes patients who initially meet diagnostic criteria for amyotrophic lateral sclerosis (ALS) or had clinical features most consistent with progressive muscular atrophy (PMA) but subsequently demonstrated substantial and sustained clinical improvement. The objective of this genome-wide association study (GWAS) was to identify correlates of this unusual clinical phenotype.
Methods
Participants were recruited from a previously created database of individuals with the ALS Reversal phenotype. Whole-genome sequencing (WGS) data were compared with ethnicity-matched patients with typically progressive ALS enrolled through the CReATe Consortium’s Phenotype-Genotype-Biomarker (PGB) study. These results were replicated using an independent ethnically matched WGS data set from Target ALS. Significant results were further explored with available databases of genetic regulatory markers and expression quantitative trait loci (eQTL) analysis.
Results
WGS from 22 participants with documented ALS Reversals was compared with the PGB primary cohort (n = 103) and the Target ALS validation cohort (n = 140). Two genetic loci met predefined criteria for statistical significance (two-sided permutation p ≤ 0.01) and remained plausible after fine-mapping. The lead single nucleotide variant (SNV) from the first locus was rs4242007 (primary cohort GWAS OR = 12.0, 95% CI 4.1 to 34.6), which is in an IGFBP7 intron and is in near-perfect linkage disequilibrium with a SNV in the IGFBP7 promoter region.
Both SNVs are associated with decreased frontal cortex IGFBP7 expression in eQTL data sets. Notably, 3 Reversals, but none of the typically progressive individuals (n = 243), were homozygous for rs4242007. The importance of the second locus, located near GRIP1, is uncertain given the absence of an associated effect on nearby gene transcription.
Discussion
We found a significant association between the Reversal phenotype and an IGFBP7 noncoding SNV that is associated with IGFBP7 expression. This is biologically relevant as IGFBP7 is a reported inhibitor of the insulin growth factor-1 (IGF-1) receptor that activates the possibly neuroprotective IGF-1 signaling pathway. This finding is limited by small sample size but suggests that there may be merit in further exploration of IGF-1 pathway signaling as a therapeutic mechanism for ALS.
Trial Registration Information
This study was registered with ClinicalTrials.gov (NCT03464903) on March 14, 2018. The first participant was enrolled on June 22, 2018.
Discussion about this post